chartexchange

MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial

PR Newswire | Nov 12, 2026 8:31 AM EST

Adding to Previously Reported 68.1% Liver Fat Reduction and Strengthening Its Liver Profile for MetALD Additional Phase 1 Part 3B Data Highlight DA-1726's 1.47 mg/dL Placebo-Adjusted Reduction in Uric Acid After 16 Weeks of Treatment (p

Read original article